NextCure director granted 2,340 stock options

NextCure, Inc. director Stephen W. Webster reported receiving a stock option grant covering 2,340 shares of common stock.

Rhea-AI Filing Summary

NextCure, Inc. director Stephen W. Webster reported receiving a stock option grant covering 2,340 shares of common stock. The option has an exercise price of $2.02 per share and expires on June 17, 2036. It vests in full on the earlier of June 18, 2027 or the 2027 Annual Meeting of Stockholders, and reflects equity compensation rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 2,340 shares

Grant/Award 1 txn

Insider Webster Stephen W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,340	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 2,340 contracts (Direct)

Footnotes (1)

1. F1. The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

Key Figures

Option grant size: 2,340 shares Exercise price: $2.02 per share Expiration date: June 17, 2036 +2 more

5 metrics

Option grant size 2,340 shares Stock option covering common stock reported for Stephen W. Webster

Exercise price $2.02 per share Conversion or exercise price of the stock option

Expiration date June 17, 2036 Option expiration date for the reported grant

Shares following transaction 2,340 options Total derivative securities held after this grant

Vesting date trigger June 18, 2027 Vests on earlier of this date or 2027 annual meeting

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Annual Meeting of Stockholders

3 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Annual Meeting of Stockholders financial

"earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NextCure (NXTC) director Stephen W. Webster report on this Form 4?

Stephen W. Webster reported receiving a stock option grant for 2,340 shares of NextCure common stock. The option is a compensation award, not an open-market trade, and gives him the right to buy shares at a fixed exercise price in the future.

What are the key terms of Stephen W. Webster’s NextCure stock option grant?

The option covers 2,340 shares of NextCure common stock at a $2.02 exercise price per share and expires on June 17, 2036. These terms define how many shares can be purchased, at what price, and until when the right remains available.

When do Stephen W. Webster’s NextCure stock options vest?

The option vests in full on the earlier of June 18, 2027 or the date of NextCure’s 2027 Annual Meeting of Stockholders. Full vesting means all 2,340 shares become exercisable at that time, subject to continued service and plan conditions.

Did Stephen W. Webster buy or sell NextCure shares in the market?

No, this filing reports a grant of stock options as compensation, not an open-market purchase or sale of NextCure shares. The transaction is coded as a grant, giving him rights to acquire shares later rather than reflecting immediate trading activity.

How many NextCure shares can be acquired under this new option grant?

The grant allows acquisition of 2,340 shares of NextCure common stock upon exercise. Each option corresponds to one underlying share, so exercising the entire award after vesting would deliver that number of shares at the stated exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Webster Stephen W

(Last) (First) (Middle)

C/O NEXTCURE, INC.

9000 VIRGINIA MANOR ROAD, SUITE 200

(Street)

BELTSVILLE MARYLAND 20705

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NextCure, Inc. [ NXTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.02	06/18/2026		A		2,340		(1)	06/17/2036	Common Stock	2,340	$0	2,340	D

Explanation of Responses:

1. The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

	/s/ Steven P. Cobourn, as attorney-in-fact for Stephen W. Webster	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)